Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
13.40
-0.51 (-3.67%)
Mar 3, 2026, 4:00 PM EST - Market closed
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 |
|---|
Developing Novel Therapeutics | 3.55M | 151.00K | | 20.10M | | 10.00M | 10.00M |
Developing Novel Therapeutics Growth | 2250.99% | - | | - | | 0% | - |
| 3.55M | 151.00K | | 20.10M | | 10.00M | 10.00M |
| 2250.99% | - | | - | | 0% | - |
Source: S&P Global Market Intelligence.
